GLP-1 and Gout: What to Know

If you use a GLP-1 medication and have heard that it might affect gout — or if you already have a gout diagnosis and are wondering how these medications relate to it — the research picture is genuinely divided. Some studies have found that GLP-1 receptor agonists may be associated with lower uric acid levels in the blood. A more recent study that looked at actual gout events, rather than blood markers alone, did not find a meaningful reduction in gout incidence among GLP-1 users. This article explains what the current evidence shows, where it disagrees, and what that means for the conversations worth having with your healthcare provider.

This article does not offer medical advice on gout treatment, medication choices, or dietary changes. Those are clinical decisions that belong with your provider.

What Gout Is, in Plain Terms

Gout is a form of inflammatory arthritis that develops when uric acid builds up in the bloodstream and forms sharp crystals in or around joints. Those crystals trigger intense inflammation — what people typically call a gout flare or gout attack. The most commonly affected joint is at the base of the big toe, though gout can also involve the ankle, knee, wrist, or other joints.

Uric acid is a natural byproduct of the body breaking down purines — compounds found in certain foods and produced through the body's own cellular processes. Most uric acid is filtered by the kidneys and cleared in urine. When the kidneys cannot clear it efficiently enough, or when production is elevated, uric acid concentrations in the blood can rise.

Gout is diagnosed by healthcare providers based on clinical evaluation, which may include blood tests measuring uric acid levels and, in some cases, examination of joint fluid. Joint pain — including the kind that some people notice during GLP-1 use — is not by itself a diagnosis of gout. If you are experiencing new or unusual joint symptoms, that is worth discussing with your provider rather than interpreting on your own. For a broader look at joint pain patterns that GLP-1 users sometimes report, the article on joint pain and GLP-1 covers that territory separately from the gout-specific research addressed here.

Why Uric Acid Comes Up in GLP-1 Conversations

The connection between GLP-1 medications and uric acid has attracted growing research interest, for several reasons.

First, weight change itself has a documented relationship with uric acid. Significant weight reduction — regardless of how it is achieved — can influence how the body processes and clears uric acid. The kidneys play a central role in uric acid elimination, and changes to kidney function or fluid balance can affect how much uric acid stays in circulation. The article on GLP-1 and kidney function covers the kidney dimension in more detail.

Second, some clinical research has explored whether GLP-1 receptor activation may have effects on uric acid levels beyond what weight change alone would explain. A 2022 systematic review and meta-analysis published in the British Journal of Clinical Pharmacology (Najafi et al.) analyzed 17 eligible studies on GLP-1 receptor agonists and serum uric acid concentration, and the findings were more layered than a simple positive signal. Comparing GLP-1 receptor agonist users to their own pre-treatment values, the analysis found a statistically significant reduction in serum uric acid (p<0.001). However, when GLP-1 receptor agonists were compared against placebo groups in controlled studies, the difference was not statistically significant (p=0.079). The analysis also found that active comparators — including insulin, metformin, and SGLT-2 inhibitors — outperformed GLP-1 receptor agonists in reducing serum uric acid concentration. The authors concluded that while GLP-1 receptor agonists can result in a reduction in serum uric acid concentration, this reduction is less than that seen with insulin, metformin, and SGLT-2 inhibitors (Najafi et al., 2022).

A commentary in the same journal by Patoulias et al., also published in 2022, offered further consideration of the mechanisms through which GLP-1 receptor agonists might influence uric acid handling — including possible direct renal effects separate from weight loss (Patoulias et al., 2022).

Third, laboratory research has pointed to a potential role for GLP-1 receptors in inflammation pathways relevant to gout. A 2022 study in Frontiers in Immunology by Chen et al. used a transgenic mouse model to examine GLP-1 receptor expression and function in macrophages during monosodium urate crystal-induced peritoneal inflammation — the type of inflammatory response that underlies gout flares. In GLP-1 receptor knockout mice, the recruitment of macrophages (particularly M2 macrophages) during MSU-induced inflammation was suppressed compared to wild-type mice. The authors concluded that the GLP-1 receptor plays a critical role in macrophage migration in MSU-induced inflammation (Chen et al., 2022). What this means for gout in humans is not established from preclinical evidence alone; the distance between mouse model findings and confirmed clinical outcomes is substantial.

These threads of evidence explain why the topic has attracted attention. They do not, by themselves, resolve the clinical question.

Where the Evidence Disagrees

The research findings described so far involve surrogate markers — primarily serum uric acid levels in blood. A lower uric acid reading is a laboratory measurement, not the same as a reduction in actual gout events.

A 2024 study published in Clinical Therapeutics addressed this distinction directly. Preston et al. analyzed healthcare data from people living with type 2 diabetes to compare gout incidence between those using GLP-1 receptor agonists and those using SGLT-2 inhibitors, across a range of treatment settings. The study found that SGLT-2 inhibitor use was associated with a reduced incidence of gout — but GLP-1 receptor agonist use was not associated with reduced gout incidence in this population (Preston et al., 2024).

This is the central tension in the current evidence: pre-to-post comparisons have associated GLP-1 receptor agonist use with reductions in serum uric acid, but the Najafi 2022 meta-analysis found no statistically significant advantage over placebo when controlled comparisons were made. And the study measuring actual gout events found no reduction in gout incidence among GLP-1 users regardless of what blood uric acid levels were doing. Surrogate marker improvement and clinical outcome improvement do not always move together — and for this question, even the biomarker signal did not clearly survive controlled comparison.

A 2025 review in Pharmaceutics by Kaufmann and Schlesinger examined the mechanisms, pharmacokinetics, and uricosuric evidence for SGLT-2 inhibitors and GLP-1 receptor agonists as potential gout treatments. On GLP-1 receptor agonists specifically, the review stated that their effect on serum uric acid levels and urinary excretion of uric acid in humans remains unclear. SGLT-2 inhibitors received more favorable characterization in the reviewed evidence. The paper's question-form title itself reflects the unsettled state of the evidence (Kaufmann & Schlesinger, 2025).

What this means practically: if you have come across claims that GLP-1 medications are beneficial for gout, that claim is not supported by the full body of current published evidence. The story is more complicated than a single direction. What to expect — and what to watch for — is a conversation that belongs with your provider, informed by your individual history.

Weight Loss Speed and Flare Risk

One aspect of GLP-1 use that has more consistent documentation in the gout and uric acid literature is the potential for rapid weight loss to temporarily increase the risk of a gout flare for some people.

GLP-1 medications can produce meaningful weight reduction over relatively short periods for some individuals. Rapid weight loss, by various mechanisms, can lead to transient increases in uric acid levels before they may eventually stabilize. This pattern has been observed with different forms of significant weight loss and is not unique to GLP-1 medications — but it is worth knowing that beginning a GLP-1 medication and experiencing rapid weight loss could, for some people with a gout history, precede a temporary increase in gout activity rather than an immediate improvement.

The mechanisms behind why rapid weight loss may transiently raise uric acid levels — and how that intersects with the body's metabolic and inflammatory responses — involve the same physiological picture discussed in the article on GLP-1 and gallbladder risk, which covers what rapid weight loss on GLP-1 treatment involves at a physiological level. That article goes into the relevant detail; the point here is that the weight-loss speed consideration exists independently of whatever direct effect GLP-1 receptor activation may or may not have on uric acid.

Hydration is also relevant in this context. Dehydration can affect how the kidneys process uric acid, and nausea during the early weeks of GLP-1 use sometimes makes adequate fluid intake harder to maintain. The article on hydration during GLP-1 use covers fluid intake considerations that are worth keeping in mind. Neither hydration management nor monitoring weight loss pace replaces working with your provider on an existing gout diagnosis.

If you notice significant joint pain, swelling, or redness during GLP-1 use — especially if severe or accompanied by fever — that warrants contacting your provider rather than monitoring at home. The article on when to call your doctor about GLP-1 side effects provides broader guidance on symptoms that merit prompt provider contact.

If You Already Have a Gout Diagnosis

If you have been diagnosed with gout and are using or considering a GLP-1 medication, a few points are worth keeping in mind — with the important caveat that clinical decisions depend on your individual history, which is a conversation for your provider.

Do not change your existing gout treatment without provider guidance. Whatever your current gout management involves — medication, monitoring schedules, or provider-directed adjustments — should continue as your provider has established unless they specifically direct otherwise. Starting or adjusting a GLP-1 medication does not change your gout management plan on its own.

Tracking your symptoms becomes more relevant. Because the relationship between GLP-1 use and gout activity is not yet clearly established in clinical evidence, logging what you observe — joint pain episodes, timing, any flares, and how they relate to changes in your GLP-1 treatment or weight trajectory — gives you and your provider useful, concrete information. Patterns captured in a log are more actionable than general impressions.

The early months of GLP-1 use may warrant closer attention. For people with a gout history who are also experiencing rapid weight loss, some providers may choose to monitor uric acid levels periodically. Whether that applies to your situation is a clinical decision that depends on factors your provider knows about your case — it is not a standardized step for all GLP-1 users with a gout history.

A new severe flare should not be managed independently. If you experience sudden intense joint pain — especially with redness, significant swelling, or fever — that is a medical concern to bring to your provider promptly, not something to observe and wait on.

Bringing Gout Up at Your Next Visit

If you have gout or a history of flares, raising this at your next provider visit is worth doing if it has not already come up. The evidence in this area is still developing, and your provider may have more recent information than any article can provide. More importantly, they have access to your full health picture — your uric acid levels, your other medications, your flare history — all of which are relevant to making sense of what GLP-1 use means for you specifically.

Some questions worth preparing before that appointment:

• "Given my history with gout, is there anything you would want to monitor while I am on a GLP-1 medication?"
• "If I notice more joint symptoms after starting or changing my GLP-1 treatment, what should I do — and when should I contact your office before my next scheduled appointment?"
• "Are there any interactions between my current gout medications and GLP-1 medications that are worth knowing about?"
• "Should we be checking uric acid levels periodically given that I am on a GLP-1 medication?"
• "The research I have read suggests that GLP-1 medications may lower uric acid in blood tests but may not reduce gout events — is that consistent with what you have seen, and does it change how you approach monitoring for me?"

Writing your questions down before the appointment helps ensure you cover what matters and leaves you with a record of the answers. If you have been logging joint pain episodes, weight trends, or any side effect patterns using our GLP-1 side-effect and progress tracker, bringing that record to your appointment gives your provider more to work with than memory alone.

This article is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any decisions about starting, stopping, or changing any medication or treatment plan. The GLP-1 Journal does not provide medical guidance and cannot advise you on your individual health situation.

Written by Joon, a health writer managing type 2 diabetes and hypertension, for The GLP-1 Journal.